Cytokinetics, Inc. (CYTK) Posts Q4 Loss of 16c/Share; Guides FY12 Revs
CYTK Hot Sheet
EPS Growth %: +27.8%Financial Fact:
Loss before income taxes: -9.93M
Today's EPS Names:
TARO, BRLI, TLB, More
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q4 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $757 thousand versus the consensus estimate of $5.62 million.
Sees FY12 revenue of $4-$5 million, versus the consensus of $4 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Sees FY12 revenue of $4-$5 million, versus the consensus of $4 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Pandora (P) Blows Up Expectations as Listener Hours Rip; Guides FY13 Ahead of Views
- NetApp (NTAP) Slammed On Weak Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
